MorphoSys AG confirmed financial guidance for the year 2022. The Company confirmed its financial guidance for the 2022 financial year. MorphoSys' most recent financial guidance for the 2022 financial year was published on March 16, 2022 and remains unchanged.

The Group expects Monjuvi's U.S. net product sales to range from USD 110 million to USD 135 million, accompanied by a gross margin of 75% to 80%. This revenue guidance does not include royalty income, milestone payments or other revenues from partners as these revenue sources are not under the company's direct control. Tremfya royalties will continue to be recorded as revenue without any cost of sales in MorphoSys' statement of profit or loss.

Royalty revenues for the sales of Tremfya will be transferred to Royalty Pharma and will therefore not result in any cash inflow for MorphoSys. MorphoSys expects to receive royalties for Minjuvi sales outside the U.S., but does not provide a prognosis for this royalty stream as MorphoSys does not receive a sales forecast from its partner Incyte.